NCT05175742View on ClinicalTrials.gov

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

PHASE2CompletedINTERVENTIONAL
Enrollment

565

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions
Covid19 Vaccine
Interventions
BIOLOGICAL

PTX-COVID19-B

Sterile solution for injection

BIOLOGICAL

Pfizer-BioNTech COVID-19 vaccine

Sterile solution for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (11)

1055

MERC Middleburg, Middleburg

1864

Wits Vaccines & Infections Diseases Analytics (VIDA) Research Unit, Johannesburg

7500

TREAD Research, Cape Town

7626

Be Part Research, Paarl

7700

UCT Lung Institute, Cape Town

T2H 2G4

LMC Clinical Research Inc. (Calgary), Calgary

L4V1P1

Malton Medical, Mississauga

K1H 1E4

Red Maple, Ottawa

M1S3V6

Pharma Medica Research Inc., Toronto

M4G3E8

Manna Bayview, Toronto

M9W4L6

Manna Toronto, Toronto

All Listed Sponsors
lead

Providence Therapeutics Holdings Inc.

INDUSTRY

NCT05175742 - PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine. | Biotech Hunter | Biotech Hunter